At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,730 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
In Brief
A Phase 3 clinical trial evaluating Empagliflozin and Placebo for Heart Failure. Completed, enrolled 3,730 participants across 520 sites in 20 countries.
Detailed Summary
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesArgentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, South Korea, Spain, United Kingdom, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionMay 2020
Study CompletionMay 2020
TodayJul 2026
First PostedFeb 20, 2017
Enrollment StartMar 6, 2017
Primary CompletionMay 1, 2020
Study CompletionMay 28, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.4 years ago
Interventions
Empagliflozindrug
once daily
Placebodrug
once daily